Manipulation and Administration of Generic and Innovative Child patient medicines - CLINical STUDy: the acceptability of and preference among four oral dosage forms in infants and preschool children in the Netherlands

ISRCTN ISRCTN63138435
DOI https://doi.org/10.1186/ISRCTN63138435
Secondary identifying numbers MAGIC CLINSTUD
Submission date
23/06/2012
Registration date
24/07/2012
Last edited
29/09/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
It can be difficult to give medicines to young children. Children may not want to take them or spit them out. However, it is very important that children swallow the full dose of a medicine. There is some evidence that the problems giving oral liquid medicines such as suspensions and syrups to young children are more profound than the problems giving oral solid flexible preparations such as powders and minitablets. Nevertheless a lot of medicines for young children are only commercially available in their liquid form. We want to study whether this approach is correct or in need of change.

Who can participate?
Parents of children aged 1 to 4 years.

What does the study involve?
Parents will be asked to administer four oral dosage forms to their child. Each dosage form should be given twice on one day. Parents will be asked to fill in a participant diary. The first domain should be filled in prior to the study. It includes questions about child and family characteristics . The second domain includes questions for each of the eight administrations as to whether the dosage form has been given, the method of administration, the child’s acceptance and the result of the intake. The third domain should be filled in at the end of the study. Parents will be asked to indicate child and parent preference plus additional comments.

What are the possible benefits and risks of participating?
The risks to the participants are considered negligible. All four dosage forms are commonly used in the Netherlands in children. The parents may refrain from administration whenever they consider this necessary, such as when they are afraid to give the mini-tablet to their child because they think the child cannot swallow it. Parents should stop offering the dosage form when the child does not want to take it. The dosage forms do not include an active substance i.e. they are placebo (dummy) medicine and this is known to the parents. Parents may explain the study purposes to their child when they consider this necessary (e.g., when the child does not understand why he has to take a medicine when he is not ill). Participating children and their parents may benefit from the study outcomes as soon as the results have been implemented and they (or their children) are in need of a real medicine. The anticipated benefits to children and their parents as a group are the availability of dosage forms that are better tailored to their needs

Where is the study run from?
The dosage forms should be administered by the parents as part of normal family routines. Thus the medicines will mostly be given at home; however, administration at other locations (e.g., when visiting grandparents etc) is also accepted.

When is the study starting and how long is it expected to run for?
The patients will be recruited in 2011 and the dosage forms should be used within their shelf-life.

Who is funding the study?
The study will be funded by two separate agencies of the Ministry of Health, Welfare and Sports in the Netherlands, namely the RIVM and the MEB. The study will be conducted in cooperation with Utrecht University and the STMR.

Who is the main contact?
Diana van Riet-Nales

Contact information

Mrs Diana van Riet-Nales
Scientific

Graadt van Roggenweg 500
Utrecht
3503 RG
Netherlands

Study information

Study designRandomised cross-over clinical trial for the type of the dosage form
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeOther
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleThe acceptability of and preference among four oral dosage forms in infants and preschool children in the Netherlands: a randomised cross-over trial
Study acronymMAGIC CLINSTUD
Study objectivesThe objective of this study is threefold:
1. To investigate the child and parent acceptance of four oral dosage forms in outpatient infants and preschool children (age 1-4 years) in the Netherlands. The dosage forms include a placebo 4-mm tablet, powder, syrup and suspension, all aimed at a neutral taste.
2. To investigate the child's and parents' preference of these dosage forms at the end of the study.
3. To investigate the impact of the child and family characteristics on the outcomes for the child and parent acceptance and preference.

The data that will be collected to enable the aforementioned three aims to be answered (e.g., how parents are administering a specific dosage form to their child when given the instruction twice daily only) may also be evaluated on their own.
Ethics approval(s)Ethical approval was waived by the Central Committee on Research involving human subjects (CCMO) on the basis of the Medical Research Involving Human Subjects Act (WMO) in the Netherlands. Hence, approval was obtained from the Institutional Review Board of the Utrecht Institute for Pharmaceutical Sciences (UIPS).

The investigator has sent an inquiry to the CCMO as to whether this trial falls under the range of the WMO and hence, whether it would be subject to medical approval.
Health condition(s) or problem(s) studiedAcceptability/preference of oral dosage forms
InterventionThe intervention will consist of the request to parents to administer four oral dosage forms to their child during normal family routines. Each dosage form should be given twice on one day in the same way the parents should administer a prescribed medicine, but without any physical or psychological compulsion.

Details of Joint Sponsor:
Medicines Evaluation Board in the Netherlands
c/o Christine Gispen
Graadt van Roggenweg 500
P.O. Box 8275, 3503 RG
Utrecht
The Netherlands
Email: cc.gispen@cbg-meb.nl
Tel: + 31 (0) 88 224 8081
Intervention typeOther
Primary outcome measure1. Child and parent acceptance
2. Child and parent preference
Secondary outcome measuresNo secondary outcome measures
Overall study start date01/01/2011
Completion date31/12/2011

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit1 Year
Upper age limit4 Years
SexBoth
Target number of participants150
Key inclusion criteriaChildren will be eligible for inclusion in this study if aged 1-4 years and if their parents have mastery of the Dutch language
Key exclusion criteria1. Mentally disabled
2. Having a condition that might have an impact on medication intake or requiring oral medication
3. Hypersensitivity to lactose, having cow's milk allergy or having an allergy of unknown origin
4. A member of staff of the preventive healthcare clinic considered that study participation was inappropriate in view of the family situation
Date of first enrolment01/01/2011
Date of final enrolment31/12/2011

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Graadt van Roggenweg 500
Utrecht
3503 RG
Netherlands

Sponsor information

Utrecht University (Netherlands)
University/education

c/o Prof. Dr. A.C.G. Egberts
Faculty of Science
Utrecht Institute for Pharmaceutical Sciences
Division Pharmacoepidemiology & Clinical Pharmacology
PO Box 80 082
Utrecht
3508 TB
Netherlands

Website http://www.uu.nl/Nl/Pages/default.aspx
ROR logo "ROR" https://ror.org/04pp8hn57

Funders

Funder type

Government

National Institute of Pubilc Health and the Environment (RIVM) (Netherlands)

No information available

Medicines Evaluation Board (Netherlands)
Government organisation / National government
Alternative name(s)
Medicines Evaluation Board, CBG
Location
Netherlands

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2013 Yes No